Skip to main content
NCBI home page
Journal of Accident & Emergency Medicine logoLink to Journal of Accident & Emergency Medicine
. 1996 May;13(3):154–162. doi: 10.1136/emj.13.3.154

The cytokine response to critical illness.

B A Foëx 1, M P Shelly 1
PMCID: PMC1342677  PMID: 8733647

Abstract

The aims of this review are to provide a basic introduction to the biology of cytokines and to summarise the results of studies, both laboratory and clinical, relating to the cytokine response to critical illness. Elucidation of the cytokine response to conditions such as sepsis, trauma, and burns may be important for several reasons. It may improve understanding of the pathophysiological processes triggered by these insults. It may allow the severity of the insult to be gauged, and maybe even provide prognostic information about individual patients. Similarly it may allow the effectiveness of resuscitation and further treatment to be monitored. Finally, knowing about the cytokine response may provide the key to developing new treatments.

Full text

PDF
154

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham E., Raffin T. A. Sepsis therapy trials. Continued disappointment or reason for hope? JAMA. 1994 Jun 15;271(23):1876–1878. doi: 10.1001/jama.271.23.1876. [DOI] [PubMed] [Google Scholar]
  2. Ayala A., Perrin M. M., Meldrum D. R., Ertel W., Chaudry I. H. Hemorrhage induces an increase in serum TNF which is not associated with elevated levels of endotoxin. Cytokine. 1990 May;2(3):170–174. doi: 10.1016/1043-4666(90)90012-i. [DOI] [PubMed] [Google Scholar]
  3. Baigrie R. J., Lamont P. M., Dallman M., Morris P. J. The release of interleukin-1 beta (IL-1) precedes that of interleukin 6 (IL-6) in patients undergoing major surgery. Lymphokine Cytokine Res. 1991 Aug;10(4):253–256. [PubMed] [Google Scholar]
  4. Baumgartner J. D., Glauser M. P., McCutchan J. A., Ziegler E. J., van Melle G., Klauber M. R., Vogt M., Muehlen E., Luethy R., Chiolero R. Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet. 1985 Jul 13;2(8446):59–63. doi: 10.1016/s0140-6736(85)90176-x. [DOI] [PubMed] [Google Scholar]
  5. Bone R. C. Monoclonal antibodies to tumor necrosis factor in sepsis: help or harm? Crit Care Med. 1993 Mar;21(3):311–312. doi: 10.1097/00003246-199303000-00001. [DOI] [PubMed] [Google Scholar]
  6. Brun-Buisson C. The HA-1A saga: the scientific and ethical dilemma of innovative and costly therapies. Intensive Care Med. 1994 May;20(5):314–316. doi: 10.1007/BF01720901. [DOI] [PubMed] [Google Scholar]
  7. Cannon J. G., Friedberg J. S., Gelfand J. A., Tompkins R. G., Burke J. F., Dinarello C. A. Circulating interleukin-1 beta and tumor necrosis factor-alpha concentrations after burn injury in humans. Crit Care Med. 1992 Oct;20(10):1414–1419. doi: 10.1097/00003246-199210000-00009. [DOI] [PubMed] [Google Scholar]
  8. Crozier T. A., Müller J. E., Quittkat D., Sydow M., Wuttke W., Kettler D. Effect of anaesthesia on the cytokine responses to abdominal surgery. Br J Anaesth. 1994 Mar;72(3):280–285. doi: 10.1093/bja/72.3.280. [DOI] [PubMed] [Google Scholar]
  9. Cruickshank A. M., Fraser W. D., Burns H. J., Van Damme J., Shenkin A. Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci (Lond) 1990 Aug;79(2):161–165. doi: 10.1042/cs0790161. [DOI] [PubMed] [Google Scholar]
  10. Damas P., Reuter A., Gysen P., Demonty J., Lamy M., Franchimont P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med. 1989 Oct;17(10):975–978. doi: 10.1097/00003246-198910000-00001. [DOI] [PubMed] [Google Scholar]
  11. Debets J. M., Kampmeijer R., van der Linden M. P., Buurman W. A., van der Linden C. J. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med. 1989 Jun;17(6):489–494. doi: 10.1097/00003246-198906000-00001. [DOI] [PubMed] [Google Scholar]
  12. Deitch E. A. Cytokines yes, cytokines no, cytokines maybe? Crit Care Med. 1993 Jun;21(6):817–819. doi: 10.1097/00003246-199306000-00003. [DOI] [PubMed] [Google Scholar]
  13. Deitch E. A., Xu D., Franko L., Ayala A., Chaudry I. H. Evidence favoring the role of the gut as a cytokine-generating organ in rats subjected to hemorrhagic shock. Shock. 1994 Feb;1(2):141–145. doi: 10.1097/00024382-199402000-00010. [DOI] [PubMed] [Google Scholar]
  14. Dhainaut J. F., Tenaillon A., Le Tulzo Y., Schlemmer B., Solet J. P., Wolff M., Holzapfel L., Zeni F., Dreyfuss D., Mira J. P. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med. 1994 Nov;22(11):1720–1728. [PubMed] [Google Scholar]
  15. Di Padova F., Pozzi C., Tondre M. J., Tritapepe R. Selective and early increase of IL-1 inhibitors, IL-6 and cortisol after elective surgery. Clin Exp Immunol. 1991 Jul;85(1):137–142. doi: 10.1111/j.1365-2249.1991.tb05694.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Dinarello C. A., Cannon J. G., Wolff S. M., Bernheim H. A., Beutler B., Cerami A., Figari I. S., Palladino M. A., Jr, O'Connor J. V. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med. 1986 Jun 1;163(6):1433–1450. doi: 10.1084/jem.163.6.1433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Elebute E. A., Stoner H. B. The grading of sepsis. Br J Surg. 1983 Jan;70(1):29–31. doi: 10.1002/bjs.1800700111. [DOI] [PubMed] [Google Scholar]
  18. Endo S., Inada K., Yamada Y., Takakuwa T., Kasai T., Nakae H., Yoshida M., Ceska M. Plasma endotoxin and cytokine concentrations in patients with hemorrhagic shock. Crit Care Med. 1994 Jun;22(6):949–955. doi: 10.1097/00003246-199406000-00012. [DOI] [PubMed] [Google Scholar]
  19. Fisher C. J., Jr, Dhainaut J. F., Opal S. M., Pribble J. P., Balk R. A., Slotman G. J., Iberti T. J., Rackow E. C., Shapiro M. J., Greenman R. L. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 1994 Jun 15;271(23):1836–1843. [PubMed] [Google Scholar]
  20. Fisher C. J., Jr, Opal S. M., Dhainaut J. F., Stephens S., Zimmerman J. L., Nightingale P., Harris S. J., Schein R. M., Panacek E. A., Vincent J. L. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med. 1993 Mar;21(3):318–327. doi: 10.1097/00003246-199303000-00006. [DOI] [PubMed] [Google Scholar]
  21. Fisher C. J., Jr, Slotman G. J., Opal S. M., Pribble J. P., Bone R. C., Emmanuel G., Ng D., Bloedow D. C., Catalano M. A., IL-1RA Sepsis Syndrome Study Group Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med. 1994 Jan;22(1):12–21. doi: 10.1097/00003246-199401000-00008. [DOI] [PubMed] [Google Scholar]
  22. Fong Y., Tracey K. J., Moldawer L. L., Hesse D. G., Manogue K. B., Kenney J. S., Lee A. T., Kuo G. C., Allison A. C., Lowry S. F. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med. 1989 Nov 1;170(5):1627–1633. doi: 10.1084/jem.170.5.1627. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hack C. E., De Groot E. R., Felt-Bersma R. J., Nuijens J. H., Strack Van Schijndel R. J., Eerenberg-Belmer A. J., Thijs L. G., Aarden L. A. Increased plasma levels of interleukin-6 in sepsis. Blood. 1989 Oct;74(5):1704–1710. [PubMed] [Google Scholar]
  24. Hoch R. C., Rodriguez R., Manning T., Bishop M., Mead P., Shoemaker W. C., Abraham E. Effects of accidental trauma on cytokine and endotoxin production. Crit Care Med. 1993 Jun;21(6):839–845. doi: 10.1097/00003246-199306000-00010. [DOI] [PubMed] [Google Scholar]
  25. Hotchkiss R. S., Karl I. E., Parker J. L., Adams H. R. Inhibition of NO synthesis in septic shock. Lancet. 1992 Feb 15;339(8790):434–435. doi: 10.1016/0140-6736(92)90127-o. [DOI] [PubMed] [Google Scholar]
  26. Joris J., Cigarini I., Legrand M., Jacquet N., De Groote D., Franchimont P., Lamy M. Metabolic and respiratory changes after cholecystectomy performed via laparotomy or laparoscopy. Br J Anaesth. 1992 Oct;69(4):341–345. doi: 10.1093/bja/69.4.341. [DOI] [PubMed] [Google Scholar]
  27. Meade P., Shoemaker W. C., Donnelly T. J., Abraham E., Jagels M. A., Cryer H. G., Hugli T. E., Bishop M. H., Wo C. C. Temporal patterns of hemodynamics, oxygen transport, cytokine activity, and complement activity in the development of adult respiratory distress syndrome after severe injury. J Trauma. 1994 May;36(5):651–657. doi: 10.1097/00005373-199405000-00009. [DOI] [PubMed] [Google Scholar]
  28. Michie H. R., Manogue K. R., Spriggs D. R., Revhaug A., O'Dwyer S., Dinarello C. A., Cerami A., Wolff S. M., Wilmore D. W. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988 Jun 9;318(23):1481–1486. doi: 10.1056/NEJM198806093182301. [DOI] [PubMed] [Google Scholar]
  29. Moore C. M., Desborough J. P., Powell H., Burrin J. M., Hall G. M. Effects of extradural anaesthesia on interleukin-6 and acute phase response to surgery. Br J Anaesth. 1994 Mar;72(3):272–279. doi: 10.1093/bja/72.3.272. [DOI] [PubMed] [Google Scholar]
  30. Moore F. A., Moore E. E., Poggetti R., McAnena O. J., Peterson V. M., Abernathy C. M., Parsons P. E. Gut bacterial translocation via the portal vein: a clinical perspective with major torso trauma. J Trauma. 1991 May;31(5):629–638. doi: 10.1097/00005373-199105000-00006. [DOI] [PubMed] [Google Scholar]
  31. Nicholson J., Grant I. S. Continuous infusion of pyridostigmine for myasthenic crisis. Crit Care Med. 1994 May;22(5):895–896. [PubMed] [Google Scholar]
  32. Patel J. P., Beck L. D., Briglia F. A., Hock C. E. Beneficial effects of combined thromboxane and leukotriene receptor antagonism in hemorrhagic shock. Crit Care Med. 1995 Feb;23(2):231–237. doi: 10.1097/00003246-199502000-00006. [DOI] [PubMed] [Google Scholar]
  33. Petros A., Bennett D., Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet. 1991 Dec 21;338(8782-8783):1557–1558. doi: 10.1016/0140-6736(91)92376-d. [DOI] [PubMed] [Google Scholar]
  34. Rabinovici R., John R., Esser K. M., Vernick J., Feuerstein G. Serum tumor necrosis factor-alpha profile in trauma patients. J Trauma. 1993 Nov;35(5):698–702. doi: 10.1097/00005373-199311000-00008. [DOI] [PubMed] [Google Scholar]
  35. Schmand J. F., Ayala A., Chaudry I. H. Effects of trauma, duration of hypotension, and resuscitation regimen on cellular immunity after hemorrhagic shock. Crit Care Med. 1994 Jul;22(7):1076–1083. doi: 10.1097/00003246-199407000-00005. [DOI] [PubMed] [Google Scholar]
  36. Shenkin A., Fraser W. D., Series J., Winstanley F. P., McCartney A. C., Burns H. J., Van Damme J. The serum interleukin 6 response to elective surgery. Lymphokine Res. 1989 Summer;8(2):123–127. [PubMed] [Google Scholar]
  37. Sori A. J., Rush B. F., Jr, Lysz T. W., Smith S., Machiedo G. W. The gut as source of sepsis after hemorrhagic shock. Am J Surg. 1988 Feb;155(2):187–192. doi: 10.1016/s0002-9610(88)80691-3. [DOI] [PubMed] [Google Scholar]
  38. Sprung C. L., Cohen J., Eidelman L. A. A plea for caution in the performance of sepsis trials. Intensive Care Med. 1995 May;21(5):389–390. doi: 10.1007/BF01707406. [DOI] [PubMed] [Google Scholar]
  39. Svoboda P., Kantorová I., Ochmann J. Dynamics of interleukin 1, 2, and 6 and tumor necrosis factor alpha in multiple trauma patients. J Trauma. 1994 Mar;36(3):336–340. doi: 10.1097/00005373-199403000-00009. [DOI] [PubMed] [Google Scholar]
  40. Tracey K. J., Fong Y., Hesse D. G., Manogue K. R., Lee A. T., Kuo G. C., Lowry S. F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987 Dec 17;330(6149):662–664. doi: 10.1038/330662a0. [DOI] [PubMed] [Google Scholar]
  41. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med. 1989 Jan 1;169(1):333–338. doi: 10.1084/jem.169.1.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Waage A., Halstensen A., Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987 Feb 14;1(8529):355–357. doi: 10.1016/s0140-6736(87)91728-4. [DOI] [PubMed] [Google Scholar]
  43. Ziegler E. J., Fisher C. J., Jr, Sprung C. L., Straube R. C., Sadoff J. C., Foulke G. E., Wortel C. H., Fink M. P., Dellinger R. P., Teng N. N. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991 Feb 14;324(7):429–436. doi: 10.1056/NEJM199102143240701. [DOI] [PubMed] [Google Scholar]
  44. Ziegler E. J., McCutchan J. A., Fierer J., Glauser M. P., Sadoff J. C., Douglas H., Braude A. I. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med. 1982 Nov 11;307(20):1225–1230. doi: 10.1056/NEJM198211113072001. [DOI] [PubMed] [Google Scholar]
  45. de Bandt J. P., Chollet-Martin S., Hernvann A., Lioret N., du Roure L. D., Lim S. K., Vaubourdolle M., Guechot J., Saizy R., Giboudeau J. Cytokine response to burn injury: relationship with protein metabolism. J Trauma. 1994 May;36(5):624–628. doi: 10.1097/00005373-199405000-00004. [DOI] [PubMed] [Google Scholar]
  46. van Deventer S. J., Büller H. R., ten Cate J. W., Aarden L. A., Hack C. E., Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 1990 Dec 15;76(12):2520–2526. [PubMed] [Google Scholar]

Articles from Journal of Accident & Emergency Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES